CN112789289A - 包含胰岛素肽和egf(a)肽的双功能化合物 - Google Patents
包含胰岛素肽和egf(a)肽的双功能化合物 Download PDFInfo
- Publication number
- CN112789289A CN112789289A CN201980064514.4A CN201980064514A CN112789289A CN 112789289 A CN112789289 A CN 112789289A CN 201980064514 A CN201980064514 A CN 201980064514A CN 112789289 A CN112789289 A CN 112789289A
- Authority
- CN
- China
- Prior art keywords
- insulin
- egf
- gaqp
- fusion protein
- gglu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18198892 | 2018-10-05 | ||
| EP18198892.4 | 2018-10-05 | ||
| PCT/EP2019/076889 WO2020070276A1 (en) | 2018-10-05 | 2019-10-04 | Bifunctional compounds comprising insulin peptides and egf(a) peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112789289A true CN112789289A (zh) | 2021-05-11 |
Family
ID=64017248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980064514.4A Withdrawn CN112789289A (zh) | 2018-10-05 | 2019-10-04 | 包含胰岛素肽和egf(a)肽的双功能化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11649269B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3861017A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7434299B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112789289A (cg-RX-API-DMAC7.html) |
| AR (1) | AR116605A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA53809A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202028229A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020070276A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115947822A (zh) * | 2022-07-04 | 2023-04-11 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其药物组合物和应用 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| HUE062719T2 (hu) | 2018-06-29 | 2023-11-28 | Akston Biosciences Corp | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások |
| KR102865175B1 (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| LT3972987T (lt) | 2020-04-10 | 2023-09-25 | Akston Biosciences Corporation | Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CA3193453A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| EP4323413A4 (en) | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009022006A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| EP2296694B1 (en) | 2008-04-23 | 2015-08-05 | Amgen Inc. | Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof |
| GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
| KR20140041747A (ko) | 2011-06-20 | 2014-04-04 | 제넨테크, 인크. | Pcsk9-결합 폴리펩티드 및 사용 방법 |
| BR112016017402A2 (pt) | 2014-02-21 | 2017-10-17 | Medimmune Ltd | fusões anti-pcsk9~glp-1 e métodos para uso |
| CN104558199B (zh) | 2014-09-05 | 2018-07-06 | 成都康弘生物科技有限公司 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| BR112018002416A2 (pt) | 2015-08-25 | 2018-09-18 | Novo Nordisk As | derivados de insulina e seus usos médicos |
| RU2747877C2 (ru) | 2016-01-13 | 2021-05-17 | Ново Нордиск А/С | Аналоги эфр(а) с заместителями - жирными кислотами |
-
2019
- 2019-10-04 EP EP19783295.9A patent/EP3861017A1/en not_active Withdrawn
- 2019-10-04 MA MA053809A patent/MA53809A/fr unknown
- 2019-10-04 CN CN201980064514.4A patent/CN112789289A/zh not_active Withdrawn
- 2019-10-04 TW TW108135986A patent/TW202028229A/zh unknown
- 2019-10-04 JP JP2021518432A patent/JP7434299B2/ja active Active
- 2019-10-04 WO PCT/EP2019/076889 patent/WO2020070276A1/en not_active Ceased
- 2019-10-04 AR ARP190102838A patent/AR116605A1/es unknown
- 2019-10-04 US US17/281,813 patent/US11649269B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115947822A (zh) * | 2022-07-04 | 2023-04-11 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其药物组合物和应用 |
| CN115947822B (zh) * | 2022-07-04 | 2023-08-18 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其药物组合物和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MA53809A (fr) | 2022-01-12 |
| US11649269B2 (en) | 2023-05-16 |
| WO2020070276A1 (en) | 2020-04-09 |
| EP3861017A1 (en) | 2021-08-11 |
| US20220009989A1 (en) | 2022-01-13 |
| AR116605A1 (es) | 2021-05-26 |
| TW202028229A (zh) | 2020-08-01 |
| JP2022504153A (ja) | 2022-01-13 |
| JP7434299B2 (ja) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11649269B2 (en) | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | |
| CN112074531B (zh) | Gip衍生物及其用途 | |
| CN101868476B (zh) | 胰高血糖素样肽-1衍生物及其制药用途 | |
| JP6657230B2 (ja) | インクレチン−インスリンコンジュゲート | |
| AU2015349890B2 (en) | Insulin receptor partial agonists | |
| KR102002783B1 (ko) | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 | |
| US9012398B2 (en) | Acylated exendin-4 compounds | |
| KR102417487B1 (ko) | 지방산 치환기를 가진 egf(a) 유사체 | |
| JP6069198B2 (ja) | N末端が修飾されたfgf21化合物 | |
| KR20110040760A (ko) | 대사 질환 및 비만 치료용 gip-기초된 혼합형 항진제 | |
| JP2012530145A (ja) | Gip受容体活性グルカゴン化合物 | |
| KR20070120112A (ko) | 연장형 glp-1 화합물 | |
| US7595294B2 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
| WO2023148366A1 (en) | Glp-1 and glucagon dual agonist peptides with improved biological stability | |
| EP2935318A1 (en) | Novel glp-1 receptor agonists with cholesterol efflux activity | |
| EP3307769B1 (en) | Protease-resistant lipidated glp-1 analogs | |
| WO2017211922A2 (en) | Protease-resistant mono-lipidated peptides | |
| JP2020527159A (ja) | Egf(a)類似体、その製造、製剤および使用 | |
| US20070293429A1 (en) | Vasoactive Intestinal Polypeptide Compositions | |
| HK1249120B (en) | Protease-resistant lipidated glp-1 analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210511 |